Has Matthew Reynolds received payments from drug or device companies?

Yes. Drug and device makers reported $207,052 in general payments to Matthew Reynolds across 816 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Matthew Reynolds did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Matthew Reynolds come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Matthew Reynolds

Medical · Russellville, ARNPI 1760855639

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $138,285 of the $207,052 with a category attached, or 66.8%. 24 manufacturers reported payments, led by Lilly USA, LLC at 30.9% of the total. Reporting peaked in 2023 at $66,934 and has fallen 71.8% since, to $18,904 in 2025. Among medical clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$207,052in general payments, 2019–2025

Across 816 payments — averaging $253.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Lilly USA, LLC$64K
Genentech USA, Inc.$47K
Sun Pharmaceutical Industries Inc.$39K
Johnson & Johnson$17K
Sanofi$11K
Regeneron Healthcare Solutions, Inc.$10K
plus $19K from 18 others

What the payments were for

Consulting fees$32,06015%
Speaking & faculty fees$138,28567%
Travel & lodging$21,15110%
Food & beverage$15,0687%
Education$4890%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Lilly USA, LLC	146	$63,959
Genentech USA, Inc.	51	$46,557
Sun Pharmaceutical Industries Inc.	102	$39,367
Johnson & Johnson	61	$17,407
Sanofi	35	$10,783
Regeneron Healthcare Solutions, Inc.	32	$10,446
LEO Pharma Inc.	66	$6,602
Janssen Scientific Affairs, LLC	10	$5,396
Novartis	64	$2,018
UCB, Inc.	114	$1,711
Pfizer	50	$918
AbbVie	32	$565
E.r. Squibb & Sons, L.L.C.	14	$385
Kyowa Kirin, Inc.	7	$234
Dermavant Sciences, Inc.	7	$154
Incyte Corporation	6	$124
Arcutis Biotherapeutics, Inc.	2	$108
Galderma Laboratories, L.p.	6	$96
Amgen	4	$63
Ortho Dermatologics, A Division Of Bausch Health US, LLC	1	$60
Boehringer Ingelheim	2	$43
Organon	2	$30
Sanofi-aventis U.S. LLC	1	$19
Biofrontera Inc.	1	$9

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

ILUMYA$37,647
Erivedge$33,879
EBGLYSS$26,908
DUPIXENT$25,772
Tremfya$21,663
TALTZ$19,672
ADBRY$5,415
LIBTAYO$3,881
XOLAIR$1,050
Winlevi$320
ABSORICA LD$320
ODOMZO$210
POTELIGEO$108
BLU-U$101

How this compares

$207,052 in reported general payments places this provider in the 95th percentile of 133 medical providers in Arkansas.

See all medical providers in Arkansas →

Medicare billing

Part B allowed, 2024

$1,736,786

Medicare patients

1,857

Services billed

36,778

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Humira(Cf) PenAdalimumab	13	$178,855
Dupixent PenDupilumab	40	$164,947
XolairOmalizumab	36	$131,363
Dupixent SyringeDupilumab	28	$104,802
Taltz AutoinjectorIxekizumab	14	$94,423
Cosentyx Sensoready (2 Pens)Secukinumab	11	$74,820
Clobetasol Propionate	122	$8,523
Triamcinolone Acetonide	178	$3,775
Imiquimod	141	$3,453
Ketoconazole	148	$3,015
Tacrolimus	23	$2,313
Doxycycline Hyclate	99	$2,205
Acitretin	13	$2,096
Metronidazole	36	$2,045
Betamethasone Dipropionate	30	$1,187

Paid to pharmacies, not to this prescriber.

Other medical in Russellville

Tara BrunerSearcy$16K
Dallas BondhusHot Springs$15K
Douglas ClarkLittle Rock$14K
Alexandra SanromaLittle Rock$11K
Caleb MasonSearcy$9K
Katherine McCradyLittle Rock$9K
Bailey PollockLittle Rock$9K
Hannah BreauLittle Rock$9K
Thurman SmithFayetteville$8K
Rebecca DennistonLittle Rock$7K

See the full list for Arkansas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →